Welcome to our dedicated page for Opthea news (Ticker: OPT), a resource for investors and traders seeking the latest updates and insights on Opthea stock.
Opthea Limited (ASX: OPT) generates frequent news as a clinical-stage biopharmaceutical company developing therapies for retinal diseases such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Company announcements describe the progress of its lead product candidate, sozinibercept, a first-in-class VEGF-C/D ‘trap’ inhibitor studied in combination with standard-of-care anti-VEGF-A therapies.
News items for OPT commonly cover clinical milestones, including Phase 2b and Phase 3 trial updates in wet AMD, early-stage data in DME, and presentations of trial results and subgroup analyses at scientific meetings and in peer-reviewed journals. Opthea also releases updates on manufacturing activities, such as completion of drug substance and drug product Process Performance Qualification campaigns to support potential regulatory filings.
Investors following OPT news will also see corporate and capital markets developments. These include half-year financial reports, cash runway commentary, capital raising outcomes, and details of a Development Funding Agreement and its subsequent settlement. The company has reported that primary endpoints were not met in its COAST and ShORe Phase 3 wet AMD trials and has described the decision, together with its DFA investors, to discontinue development of sozinibercept in wet AMD, along with workforce reductions, management changes, and a planned strategic review.
Regulatory and listing updates also appear in Opthea’s news flow, such as announcements related to its intention to voluntarily delist American Depositary Shares from The Nasdaq Global Select Market. For readers interested in the intersection of ophthalmology, clinical trial data, and biotech corporate strategy, the OPT news feed provides ongoing context on Opthea’s programs and corporate actions.
Opthea Limited (NASDAQ:OPT; ASX:OPT) announced that CEO Dr. Megan Baldwin will present at the Jefferies London Healthcare Conference on November 15, 2022, at 7:25 AM GMT (6:25 PM AEDT). The presentation will be accessible via a live audio webcast for 90 days on Opthea's Investors page. The company focuses on developing therapies for retinal diseases such as wet AMD and diabetic macular edema. Its lead product, OPT-302, is currently in Phase 3 clinical trials aimed at enhancing treatment efficacy when used with anti-VEGF-A therapies.
Opthea Limited (NASDAQ:OPT), a biopharmaceutical company focused on retinal diseases, announced the appointment of Timothy E. Morris as Chief Financial Officer effective October 24, 2022. With over 25 years of experience in public biotechnology, Morris has a proven track record in raising over $2.5 billion for several companies. His expertise is expected to enhance Opthea's financial strategy as it progresses towards Phase 3 trials for its lead product, OPT-302. The company aims to improve treatment options for wet age-related macular degeneration and diabetic macular edema.
Opthea Limited (ASX:OPT; NASDAQ:OPT) secured up to US$170 million in non-dilutive financing, with commitments for US$90 million in equity financing, completing a first tranche of US$41.9 million. The company is advancing its Phase 3 clinical trials for OPT-302 targeting wet AMD, aiming to complete patient recruitment by mid-CY2023 and report topline data by mid-CY2024. For the fiscal year ending June 30, 2022, Opthea reported a net loss of US$92.8 million. The management team has been expanded with new C-Suite appointments and board members.
MELBOURNE, Australia, Aug. 16, 2022 - Opthea Limited (ASX:OPT; NASDAQ:OPT) announces that CEO Dr. Megan Baldwin will speak at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022. The presentation can be accessed on the Opthea website for 90 days starting at 7:00 AM ET (9:00 PM AET). Opthea is developing novel therapies for retinal diseases like wet AMD and DME, with its lead candidate OPT-302 currently in pivotal Phase 3 trials, aiming to enhance treatment efficacy against VEGF family inhibitions. Investments in biotechnology carry inherent risks.
Opthea Limited (ASX:OPT; NASDAQ:OPT) announced binding commitments for a two-tranche placement to raise approximately US$90 million (A$128.57 million) at A$1.15 per share, a 12.6% discount to the VWAP. A concurrent non-dilutive financing of up to US$170 million with Carlyle and Abingworth will support clinical trials for OPT-302, targeting wet age-related macular degeneration. The first tranche, generating US$42.5 million, is set for settlement on August 24, 2022, while the second is pending shareholder approval on September 26, 2022. Additionally, an SPP will allow eligible shareholders to purchase shares without fees.
Opthea Limited (ASX: OPT; NASDAQ: OPT) has announced a strategic non-dilutive financing deal worth up to US$170 million with Carlyle and Abingworth through Launch Therapeutics. The agreement includes an initial US$120 million commitment and an option for an additional US$50 million, aimed at advancing OPT-302's Phase 3 clinical trials for wet age-related macular degeneration (wet AMD). If OPT-302 is approved, these investors could receive milestone and variable payments based on net sales. Opthea also launched a US$90 million private placement and a US$5 million Share Purchase Plan.
Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company, announced CEO Dr. Megan Baldwin will present at two investor conferences in May 2022. The events include the Citi Biopharma Virtual Co-Panel Day on May 18, 2022, at 4:30 pm ET and the H.C. Wainwright Annual Global Life Sciences Conference on May 24, 2022, at 7:00 am ET. Both presentations will be available on the Investors page of Opthea's website for 90 days. Opthea focuses on developing therapies for retinal diseases, with its lead candidate OPT-302 in pivotal Phase 3 trials.
Opthea Limited (ASX:OPT; NASDAQ:OPT) announced a presentation at the Retina World Congress 2022, scheduled for May 12-15 in Fort Lauderdale, Florida. Dr. David Boyer will discuss OPT-302 Combination Therapy for wet AMD during a Phase 3 program aimed at demonstrating superiority over anti-VEGF-A monotherapy. The presentation will highlight the potential of OPT-302 to enhance treatment efficacy in retinal diseases, particularly in achieving superior vision gains.
The company emphasizes that its lead candidate is undergoing pivotal trials to address unmet medical needs.
Opthea Limited (ASX:OPT; Nasdaq: OPT) presented clinical data at the ARVO 2022 Annual Meeting regarding OPT-302's efficacy in treating Polypoidal Choroidal Vasculopathy (PCV). Dr. Jason Slakter presented findings showing that OPT-302 combined with ranibizumab yielded superior visual acuity gains compared to ranibizumab alone. Of 366 participants, 18% had PCV lesions. The combination therapy achieved an additional 6.7 letter gain in vision over six months. Positive feedback has been received, and ongoing Phase 3 trials are expected to enroll significant numbers of treatment-naïve patients.
Opthea Limited (ASX:OPT; NASDAQ:OPT) announced it will present novel clinical data at the ARVO 2022 conference in Denver, CO from May 1-4, 2022. Dr. Jason Slakter will present findings from a Phase 2b trial regarding OPT-302's safety and efficacy for polypoidal choroidal vasculopathy (PCV) alongside ranibizumab (Lucentis®). This trial aims to better address the treatment of progressive retinal diseases. Opthea's lead candidate, OPT-302, is currently in pivotal Phase 3 trials, focused on improving vision gains compared to standard therapies.
FAQ
What is the current stock price of Opthea (OPT)?
What is the market cap of Opthea (OPT)?
